1.
Long recovery from mass extinction seen
PARIS, June 22 (UPI) -- A French study shows the drug masitinib, being developed for the treatment of rheumatoid arthritis, appears to be well tolerated and effective, researchers say.
The clinical trial, led by Olivier Hermine of Necker Hospital in Paris, included 43 patients with arthritis resistant to current treatments.
"In choosing which interventions to use for the management of rheumatoid arthritis, it is important to recognize that treatment should aim to keep the disease in remission and not be used intermittently to manage exacerbations," said Hermine. "We are encouraged from this study that masitinib not only appears to be effective, but that within the first three months of treatment the worst of its side effects were over, possibly making it suitable for long-term treatment regimens"
The researcher said the study also helps establish the critical role of mast cells in the pathogenesis of rheumatoid arthritis and demonstrate their viability as a therapeutic target.
The clinical trial is reported in the journal Arthritis Research and Therapy.
|
|
|
|
|
|
| Additional Science News Stories | |
MIAMI, May 30 (UPI) --
The man who bit off parts of the face of a homeless man in Miami found his victim sleeping in the shade of elevated train tracks, video footage shows.
|
LOS ANGELES, May 30 (UPI) --
Actor Tim Daly said via Twitter his character Pete Wilder won't be on next season of the U.S. medical drama, "Private Practice."
|
ITHACA, N.Y., May 30 (UPI) --
The genome of the tomato has been decoded, a step toward improving yield, nutrition, disease resistance, taste and color of the tomato, U.S. researchers say.
|
TUCSON, May 30 (UPI) --
An Arizona woman said her 8-year-old daughter was humiliated to receive the "Catastrophe Award" from her teacher for giving the most homework excuses.
|
| Stories | Photos | People | Comments |
View Caption
